Let’s start up with the current stock price of Intra-Cellular Therapies, Inc. (ITCI), which is $26.20 to be very precise. The Stock rose vividly during the last session to $26.7 after opening rate of $25.68 while the lowest price it went was recorded $25.5 before closing at $25.86.
Intra-Cellular Therapies, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $43.56 on 12/23/19, with the lowest value was $6.75 for the same time period, recorded on 10/01/19.
Intra-Cellular Therapies, Inc. (ITCI) full year performance was 107.61%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intra-Cellular Therapies, Inc. shares are logging -39.85% during the 52-week period from high price, and 288.15% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.75 and $43.56.
The company’s shares, operating in the sector of healthcare managed to top a trading volume set approximately around 800326 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Intra-Cellular Therapies, Inc. (ITCI) recorded performance in the market was -23.64%, having the revenues showcasing 68.71% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.64B, as it employees total of 330 workers.
Market experts do have their say about Intra-Cellular Therapies, Inc. (ITCI)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 19.70, with a change in the price was noted +3.60. In a similar fashion, Intra-Cellular Therapies, Inc. posted a movement of +15.93% for the period of last 100 days, recording 892,775 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity. The total Debt to Equity ratio for ITCI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Intra-Cellular Therapies, Inc. (ITCI)
Raw Stochastic average of Intra-Cellular Therapies, Inc. in the period of last 50 days is set at 87.56%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 82.65%. In the last 20 days, the company’s Stochastic %K was 83.04% and its Stochastic %D was recorded 87.75%.
Bearing in mind the latest performance of Intra-Cellular Therapies, Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -23.64%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -31.93%, alongside a boost of 107.61% for the period of the last 12 months. The shares increased approximately by 7.89% in the 7-day charts and went down by 9.58% in the period of the last 30 days. Common stock shares were driven by 68.71% during last recorded quarter.